Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker.
about
Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A₂ (Lp-PLA₂): a reviewMolecular Model of Plasma PAF Acetylhydrolase-Lipoprotein Association: Insights from the Structure.Lipoprotein-associated phospholipase A2 and risk of dementia in the Cardiovascular Health StudyRacial variation in lipoprotein-associated phospholipase A₂ in older adults.Peripheral arterial tonometry for risk stratification in men with coronary artery diseaseLipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection.Circulating platelet-activating factor is primarily cleared by transport, not intravascular hydrolysis by lipoprotein-associated phospholipase A2/ PAF acetylhydrolaseLipoprotein associated phospholipase A(2): role in atherosclerosis and utility as a biomarker for cardiovascular risk.Novel and conventional biomarkers for prediction of incident cardiovascular events in the community.Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and AtherosclerosisTranslational studies of lipoprotein-associated phospholipase A₂ in inflammation and atherosclerosis.Biomarkers and their involvement in the early diagnosis of right ventricular dysfunction in type 2 Diabetes MellitusHeart disease is common in humans and chimpanzees, but is caused by different pathological processes.Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies.Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease.Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, platelet-activating factor acetylhydrolase (PAF-AH) in leukocytes and body composition in healthy adults.High-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 stability before and after stroke and myocardial infarction.The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.Invited article: searching for oracles? Blood biomarkers in acute stroke.Lipoprotein-associated phospholipase A2, a novel cardiovascular inflammatory marker, in HIV-infected patients.Baseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement.Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker.Exploring the plasmatic platelet-activating factor acetylhydrolase activity in patients with anti-phospholipid antibodies.Darapladib: an emerging therapy for atherosclerosis.The incremental value of lipids and inflammatory biomarkers in determining residual cardiovascular risk.The role of intima-media-thickness, ankle-brachial-index and inflammatory biochemical parameters for stroke risk prediction: a systematic review.Lipoprotein-associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker.Cardiovascular Disease Risk Assessment: Review of Established and Newer Modalities.Comparative Proteomic Analysis of Two Differently Extracted Coptis chinensis in the Treatment of Type 2 Diabetic Rats
P2860
Q26991853-D36E1326-C151-4D16-8E9C-9F1C6F9E9CA4Q33664201-175B6B27-1DE3-4008-BFB0-0AD46FC392C3Q33895897-E8A676C3-6298-4D9A-B250-C2C26263F27CQ33946023-35E95911-13EB-4963-A770-AA530734D9A2Q34038387-B24206EC-C405-4041-ACB4-816C3BF50CAEQ34214336-02D578BF-1277-448E-9B18-6817FBF82BBAQ34670677-76976837-23B9-4433-955D-E99FF5923909Q34890672-759E5B39-0B43-44F7-B6EA-F519022CDEF0Q34960396-059364D9-B2EC-4207-898B-68548B103925Q35764402-46D82469-283F-4CBF-8784-DA03CD42B9F6Q35774358-976BE9C2-C6A8-42D1-BAD8-DD047DC76730Q35838354-8884DA0B-44F4-43F5-98B2-65142480C76BQ35960796-25804A59-7604-4EF1-9681-DD46CF370F1FQ36609778-2D83695F-FB37-4537-85F8-B603ECD466C6Q36835900-8F721FFE-C86F-4077-9B05-F6253DA48C19Q37244962-94436DF8-9598-4726-A6F0-E9823646F98DQ37386842-78AF86D1-9268-40E3-88F5-5E6C1B44874EQ37491763-3CF3BFD3-55A4-4816-96F6-CBD5E98081FFQ37571237-DCE1722D-24D0-492A-AD53-69A58E2AC669Q37604527-7B8258EE-65AE-480F-B920-167DCE3BA73AQ37685077-84BB5C33-6666-495F-ADDD-33C8B0D9A99DQ37707415-E78B1140-59A8-4C9F-8E10-1A21A352FDC4Q37720776-7A7F051C-98EC-4195-8E11-4CEA8021A81DQ37775820-EB46E65E-0E4F-4657-AF1E-52F6C270D1B3Q37902963-00C08360-D064-4D0D-AC2D-78154E01CFD3Q37927179-A68CCB48-708C-4C41-B78A-4B2BE2DCC202Q37991749-0D3BCE68-A22D-4EFA-9A7B-2076A067B61FQ38608589-CFEE4891-B884-4C29-8501-6001F6FDB171Q57300387-9824E234-CB9E-4C65-B3B0-6D1839390B7B
P2860
Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Review of the evidence for the ...... a cardiovascular risk marker.
@en
Review of the evidence for the ...... a cardiovascular risk marker.
@nl
type
label
Review of the evidence for the ...... a cardiovascular risk marker.
@en
Review of the evidence for the ...... a cardiovascular risk marker.
@nl
prefLabel
Review of the evidence for the ...... a cardiovascular risk marker.
@en
Review of the evidence for the ...... a cardiovascular risk marker.
@nl
P2093
P1476
Review of the evidence for the ...... a cardiovascular risk marker.
@en
P2093
Marshall A Corson
Michael H Davidson
Peter H Jones
P304
P356
10.1016/J.AMJCARD.2008.04.018
P407
P577
2008-06-01T00:00:00Z